Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria
- 13 May 2006
- journal article
- review article
- Published by Springer Nature in Diabetologia
- Vol. 49 (7) , 1467-1476
- https://doi.org/10.1007/s00125-006-0279-3
Abstract
There is concern that antipsychotic drugs cause diabetes. Although there has been an explosion in the quantity of literature about this subject, it remains confusing and inconsistent. To assess whether the association between antipsychotic drugs and diabetes is causative, we applied the Austin Bradford Hill criteria to the available evidence. In support of a causative relationship, there is temporality for some cases of diabetes, and there is a biologically plausible explanation. The causative link between antipsychotic drugs and diabetes is coherent with our understanding of diabetes and there are other analogies. However the strength of association is weak, there is lack of consistency or specificity, and there is little evidence to support a biological gradient. We should therefore conclude that the evidence surrounding a causative link between antipsychotic drugs and diabetes is inconclusive. Moreover, the risk is probably low and the attributable risk of developing diabetes is greater for traditional risk factors such as family history, ethnicity, obesity and ageing than it is for receiving an antipsychotic drug. Consequently, the majority of patients receiving second-generation antipsychotics will not develop diabetes as a result of their medication.Keywords
This publication has 76 references indexed in Scilit:
- Association between antipsychotic drugs and diabetesDiabetes, Obesity and Metabolism, 2005
- Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case‐control study of California Medicaid claimsPharmacoepidemiology and Drug Safety, 2005
- Testing for diabetesThe British Journal of Psychiatry, 2005
- Antipsychotics and diabetes: Review of non-prospective dataThe British Journal of Psychiatry, 2004
- Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With SchizophreniaAmerican Journal of Psychiatry, 2003
- Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs ChlorpromazineNeuropsychopharmacology, 2003
- Causal Association in Pharmacovigilance and PharmacoepidemiologyDrug Safety, 2002
- The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in EnglandJournal of Psychopharmacology, 2001
- Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trialInternational Journal of Neuropsychopharmacology, 1999
- Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patientsInternational Journal of Neuropsychopharmacology, 1999